MOESM3 of A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

Additional file 3: Figure S3. Serum cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels in the 4 patients with durable stable disease in this study. Their levels remained consistent throughout this study in all 4 patients

MOESM2 of A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

Additional file 2: Figure S2. Serum marker levels in Patient 11 who developed rhadbomyolysis on study. Baseline and Day 6 (erlotinib only) serum levels in the normal range for alanine transaminase (ALT), albumin and CPK, measures of hepatic, renal and muscle health, respectively. However at Day 28 (erlotinib and rosuvastatin treatment), significant increases in all three-serum markers were observed, particularly with CPK levels, which increased from 60U/L to over 2000U/L, suggesting rosuvastatin-induced muscle damage

Additional file 1: of Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Supplementary methods and Tables S1–S4. (DOCX 148 kb